The accreditors of this session require that you periodically check in to verify that you are still attentive.
Please click the button below to indicate that you are.
Sp299
ADDICTION TREATMENT AND HARM REDUCTION IN VIRAL HEPATITIS
Date
May 18, 2024
Explore related products in the following collection:
BACKGROUND: Approximately 40% of primary biliary cholangitis (PBC) patients exhibit poor response to ursodeoxycholic acid (UDCA) and prognosis, referred to as refractory PBC. There is an urgent need to explore new treatment approaches for this patient population…